i-FACTOR
Commercial- Indications
- Cervical spine fusion
Company intelligence / Profile preview
Cerapedics
Westminster, Colorado, United Statescerapedics.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Cerapedics’ i‑FACTOR Peptide Enhanced Bone Graft is FDA-approved for single-level ACDF and has demonstrated superior long-term outcomes compared to local autograft, with a 98.6% six-year spinal fusion rate. The company’s next-generation P‑15 Bone Graft is in pivotal trials for lumbar interbody fusion and has received Breakthrough Device Designation from the FDA.
- Therapeutic areas
- OtherNeurology
- Modalities
- DevicePeptidesBiologic (peptide-enhanced bone graft)
- Industry
- Implantable Medical Devices
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Beyond the preview
Go deeper on Cerapedics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cerapedics.